In a review  published in this journal in 2014 we updated the role of statin treatment in patients with
type 2 diabetes mellitus (T2DM). This is an important topic because the prevalence of T2DM is increasing and this
disease is associated with a high risk of cardiovascular disease (CVD) as well as microvascular complications .
The relationship between T2DM and statins is further complicated since these drugs can cause new onset diabetes
(NOD) although there is an overall benefit in terms of preventing vascular events [1, 2]. The cost implications of
T2DM in terms of quality of life as well as providing healthcare are obvious. This is a brief update of our earlier
review  based on recently published data.
Keywords: IMPROVE-IT, diabetes mellitus, cancer, statins, new onset diabetes, ezetimibe.
Rights & PermissionsPrintExport